ArticleDiagnostic and interventional radiology (Ankara, Turkey)2020
Percutaneous cryoablation in early stage hepatocellular carcinoma: analysis of local tumor progression factors.
Article in Diagnostic and interventional radiology (Ankara, Turkey), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Percutaneous Cryoablation Versus Microwave Ablation for Hepatocellular Carcinoma: Comparative Study of Safety and Oncologic Outcomes.Radiology. Imaging cancer · 2026Article
- Clinical significance of contrast extravasation on computed tomography immediately after thermal ablation for hepatic tumors.BMC gastroenterology · 2025Article
- Molecular MRI of T-cell immune response to cryoablation in immunologically hotJHEP reports : innovation in hepatology · 2025Article
- Precision oncology: The role of minimally-invasive ablation therapy in the management of solid organ tumors.World journal of radiology · 2025Review
- Optimizing Treatment Selection for Early Hepatocellular Carcinoma Based on Tumor Biology, Liver Function, and Patient Status.Journal of hepatocellular carcinoma · 2025Review
- Thermal Ablation in the Liver: Heat versus Cold-What Is the Role of Cryoablation?Seminars in interventional radiology · 2023Review
- Generic surgical process model for minimally invasive liver treatment methods.Scientific reports · 2022Article
- Advances in the interventional therapy of hepatocellular carcinoma originating from the caudate lobe.Journal of interventional medicine · 2022Article
- Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV.Infectious disease reports · 2022Review
- Chemo-immunoablation of solid tumors: A new concept in tumor ablation.Frontiers in immunology · 2022Review
- Percutaneous Cryoablation of Liver Tumors: Initial Experience from a Tertiary Care Center in India.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe aimed to evaluate the effectiveness and safety of percutaneous cryoablation (PC) for early or very early stage hepatocellular carcinoma (HCC) and assess the risk factors for local tumor progression (LTP) after PC.
methodsA total of 45 treatment-naïve patients treated with PC for early or very early stage HCCs were included in this retrospective study. The safety of PC was assessed by evaluating procedure-related complications and comparing hepatic function before and after the procedure. The effectiveness was assessed by evaluating technical success, LTP rates, and disease progression (DP) rates. Prognostic factors associated with LTP after PC were also analyzed.
resultsTechnical success and complete response were achieved in all patients (100%) by 1 month after PC. During a mean of 28.1±15.6 months of follow-up, the incidences of LTP and DP were 11.1% and 37.8%, respectively. The LTP-free and DP-free survival rates were 93.3% and 84.4% at 1 year and 88.9% and 62.2% at 2 years, respectively. Hepatic function was normalized within 3 months after PC. There were no major complications and only one minor complication of small hematoma. On univariate and multivariate analysis, minimal ablative margin <5 mm was the only significant risk factor associated with LTP.
conclusionPC is a safe and effective therapy for patients with early or very early stage HCC. Minimal ablative margin <5 mm was a significant prognostic factor for LTP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.